Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva

Armata Pharmaceuticals, Inc.

• Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.
• Entered $15M secured credit agreement with Innoviva at 14% interest, matures Jan 2029; proceeds to fund AP-SA02 development.
• Positive topline results from Phase 1b/2a diSArm trial: met primary endpoints, improved clinical outcomes, no treatment-related SAEs.
• Received additional $4.65M non-dilutive funding from U.S. Department of Defense through MTEC.
• Plans end-of-Phase 2 meeting with FDA in H2 2025; expects to start Phase 3 pivotal trial in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.